RU2418807C2 - Соединения, связывающие bir домены iap - Google Patents

Соединения, связывающие bir домены iap Download PDF

Info

Publication number
RU2418807C2
RU2418807C2 RU2008120408/04A RU2008120408A RU2418807C2 RU 2418807 C2 RU2418807 C2 RU 2418807C2 RU 2008120408/04 A RU2008120408/04 A RU 2008120408/04A RU 2008120408 A RU2008120408 A RU 2008120408A RU 2418807 C2 RU2418807 C2 RU 2418807C2
Authority
RU
Russia
Prior art keywords
alkyl
aryl
compound according
optionally substituted
substituents
Prior art date
Application number
RU2008120408/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008120408A (ru
Inventor
Алэн ЛОРЕН (CA)
Алэн ЛОРЕН
Ким ХЬЮИТТ (CA)
Ким ХЬЮИТТ
Стефен МОРРИС (CA)
Стефен МОРРИС
Патрик БЮРО (CA)
Патрик БЮРО
Алэн БУДРЕО (CA)
Алэн БУДРЕО
Скотт ДЖАРВИС (CA)
Скотт ДЖАРВИС
Джеймс Б. ДЖАКУИТ (CA)
Джеймс Б. ДЖАКУИТ
Original Assignee
Аегера Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аегера Терапьютикс Инк. filed Critical Аегера Терапьютикс Инк.
Publication of RU2008120408A publication Critical patent/RU2008120408A/ru
Application granted granted Critical
Publication of RU2418807C2 publication Critical patent/RU2418807C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2008120408/04A 2005-10-25 2006-10-20 Соединения, связывающие bir домены iap RU2418807C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72972705P 2005-10-25 2005-10-25
US60/729,727 2005-10-25
US83066206P 2006-07-14 2006-07-14
US60/830,662 2006-07-14

Publications (2)

Publication Number Publication Date
RU2008120408A RU2008120408A (ru) 2009-12-10
RU2418807C2 true RU2418807C2 (ru) 2011-05-20

Family

ID=37965208

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008120408/04A RU2418807C2 (ru) 2005-10-25 2006-10-20 Соединения, связывающие bir домены iap

Country Status (10)

Country Link
US (4) US7589118B2 (https=)
EP (1) EP1951698A4 (https=)
JP (1) JP2009512719A (https=)
KR (1) KR20080067357A (https=)
AU (1) AU2006308453B9 (https=)
BR (1) BRPI0617751A2 (https=)
CA (1) CA2564872C (https=)
IL (1) IL190936A0 (https=)
RU (1) RU2418807C2 (https=)
WO (1) WO2007048224A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274937B2 (en) * 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0708942A2 (pt) * 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20130150A1 (es) * 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
US20120141496A1 (en) * 2007-12-17 2012-06-07 Aegera Therapeutics, Inc. Iap bir domain binding compounds
ES2398791T3 (es) * 2008-01-11 2013-03-21 Genentech, Inc. Inhibidores de IAP
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009155709A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102171209A (zh) * 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8779280B2 (en) * 2009-08-18 2014-07-15 Lg Electronics Inc. Solar cell and method of manufacturing the same
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
NZ602392A (en) * 2010-03-18 2014-03-28 Innopharma Inc Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN113677399B (zh) * 2019-04-05 2024-10-11 和博医药有限公司 凋亡蛋白抑制剂的二价拮抗剂
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
WO2024165017A1 (zh) * 2023-02-08 2024-08-15 成都先导药物开发股份有限公司 杂环化合物及其用途
KR102848239B1 (ko) * 2023-04-13 2025-08-19 성신여자대학교 연구 산학협력단 비천연 아미노산을 포함하는 htra 표적 테트라펩타이드 프로브

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20050197403A1 (en) * 2004-03-01 2005-09-08 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
RU2007104028A (ru) * 2004-07-02 2008-08-10 Дженентек, Инк. (Us) Ингибиторы iap

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680077B2 (ja) 1985-02-08 1994-10-12 サントリー株式会社 プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物
US5750646A (en) * 1987-09-24 1998-05-12 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
GB9016810D0 (en) 1990-07-31 1990-09-12 Wellcome Found Peptides
JPH04208299A (ja) 1990-11-30 1992-07-29 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
US5387671A (en) 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
KR100213201B1 (ko) * 1996-05-15 1999-08-02 윤종용 씨모스 트랜지스터 및 그 제조방법
US6423689B1 (en) 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
BRPI9911756B1 (pt) 1998-06-30 2016-06-14 Helsinn Healthcare Sa composto, uso do mesmo, e composição farmaceutica
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
KR20060126548A (ko) 2004-02-05 2006-12-07 노파르티스 아게 (ａ) ＤＮＡ 토포이소머라제 억제제 및 (ｂ) ＩＡＰ 억제제조합물
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
US7772177B2 (en) * 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
EP1888619B1 (en) 2005-05-25 2013-04-17 2cureX ApS Compounds modifying apoptosis
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2007075525A2 (en) 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
BRPI0708942A2 (pt) 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc composto promotor de apoptose, uso e mÉtodo de produÇço do mesmo e composiÇço farmacÊutica
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090041391A (ko) 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
KR20090082221A (ko) 2006-10-19 2009-07-29 노파르티스 아게 유기 화합물
CN101541325A (zh) 2006-11-28 2009-09-23 诺瓦提斯公司 Iap抑制剂用于治疗急性髓性白血病的用途
KR20090087094A (ko) 2006-11-28 2009-08-14 노파르티스 아게 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물
ATE542798T1 (de) 2006-12-07 2012-02-15 Novartis Ag Organische verbindungen
US8063218B2 (en) 2006-12-19 2011-11-22 Genentech, Inc. Imidazopyridine inhibitors of IAP
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
WO2008144925A1 (en) 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9750729B2 (en) 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
TW201011006A (en) 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US20110177060A1 (en) 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20050197403A1 (en) * 2004-03-01 2005-09-08 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
RU2007104028A (ru) * 2004-07-02 2008-08-10 Дженентек, Инк. (Us) Ингибиторы iap

Also Published As

Publication number Publication date
US7547724B2 (en) 2009-06-16
AU2006308453A1 (en) 2007-05-03
AU2006308453A8 (en) 2008-05-29
IL190936A0 (en) 2009-09-22
AU2006308453B9 (en) 2011-12-01
US8063095B2 (en) 2011-11-22
KR20080067357A (ko) 2008-07-18
EP1951698A1 (en) 2008-08-06
US20070219140A1 (en) 2007-09-20
US20080014207A1 (en) 2008-01-17
CA2564872A1 (en) 2007-04-25
AU2006308453B2 (en) 2011-07-28
US7795298B2 (en) 2010-09-14
JP2009512719A (ja) 2009-03-26
US20070093429A1 (en) 2007-04-26
CA2564872C (en) 2010-12-21
BRPI0617751A2 (pt) 2011-08-02
US7589118B2 (en) 2009-09-15
WO2007048224A1 (en) 2007-05-03
US20070093428A1 (en) 2007-04-26
EP1951698A4 (en) 2010-04-28
RU2008120408A (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
RU2418807C2 (ru) Соединения, связывающие bir домены iap
KR102849047B1 (ko) 피롤로피리미딘 itk 억제제
ES2899922T3 (es) Compuestos de indazol piridona fusionados como antivirales
CN112204029A (zh) 治疗性化合物
BRPI0406801B8 (pt) derivados de tieno-pirimidinodiona e uso dos mesmos na modulação de doenças autoimunes
EA200801041A1 (ru) Ингибиторы мек и способы их применения
EA199801047A1 (ru) Замешенные призводные инлазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
WO2016210289A1 (en) Chemical modulators of signaling pathways and therapeutic use
AR018311A1 (es) Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas.
EA199900022A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
EA199900183A1 (ru) Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
DK0652868T3 (da) Hæmmere af c-AMP-phosphodiesterase
KR20180048635A (ko) Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
EA200700099A1 (ru) Производные пиридина
CN104837825A (zh) 鲁顿酪氨酸激酶抑制剂
BG104813A (bg) Заместени индолинони с инхибиращ ефект върху кинази и комплекси циклин/cdk
BR112012008849A2 (pt) composto, composição farmacêutica, e, uso de um composto
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
ES3056588T3 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
CN112513020A (zh) 用于治疗疾病的kdm1a抑制剂
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
EA200701113A1 (ru) Макролиды
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
CN114206861A (zh) 用作ripk1抑制剂的稠环杂芳基化合物

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20120413

MM4A The patent is invalid due to non-payment of fees

Effective date: 20131021